CNMD

CONMED Corp. 10-Q Summary: Quarter Ended March 31, 2005

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2005, for CONMED Corporation, a medical technology company specializing in instruments, implants, and video equipment for arthroscopic sports medicine, powered surgical instruments, and electrosurgery systems. The company operates through five principal units aggregated into a single segment. International sales accounted for 38% of total net sales during the period.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 16.3% ($21.9 million) year-over-year. This was driven primarily by the Bard Endoscopic Technologies acquisition ($14.3 million) and favorable foreign currency exchange rates ($1.8 million). Organic growth occurred across Arthroscopy, Powered Surgical Instruments, and Endosurgery lines.
• Margin Compression: Gross profit margin decreased from 52.5% to 51.6%. This decline is attributed to $2.3 million in acquisition-related charges included in cost of sales, specifically inventory step-up costs and higher transition costs for products manufactured by C.R. Bard.
• Operating Expenses: Selling and administrative expenses rose to $52.5 million (33.7% of sales) from $43.8 million (32.7% of sales), due to litigation costs (Johnson & Johnson antitrust suit), Sarbanes-Oxley compliance, and the integration of the new Endoscopic Technologies business.
• Other Expenses: The company recorded $1.9 million in "Other expense," consisting of $1.4 million in acquisition-related charges and $0.5 million for the termination of a surgical lights product line. No such expense was recorded in Q1 2004.
• Net Income Decline: Despite higher sales, net income fell 10.6% due to the aforementioned acquisition costs, increased operating expenses, and higher interest expense ($3.8 million vs. $3.3 million) resulting from debt financing the Bard acquisition.

Guidance, Outlook, and Risks

• Acquisition Integration: Manufacturing for the Bard Endoscopic Technologies products is transitioning from C.R. Bard to CONMED facilities, expected to complete in 2006. Costs are currently elevated during this transition.
• Capital Expenditures: Management expects capital expenditures to approximate $12.0 million to $15.0 million for the full year 2005, up from $4.0 million in Q1, to support manufacturing expansion.
• Stock Repurchases: The company plans to repurchase $7.7 million of common stock in Q2 2005 to offset dilution from employee stock plans, funded by cash on hand.
• Legal Risks: CONMED is pursuing an antitrust lawsuit against Johnson & Johnson regarding endoscopic surgery products. While management believes the claims are well-grounded, there is no assurance of success, and litigation costs may be material.
• Accounting Changes: The company is evaluating the impact of SFAS 123R (Share-Based Payment), required to be adopted by January 1, 2006, which will likely increase reported compensation expenses.
• Pension Costs: Pension expense is estimated at $4.5 million for 2005, an increase from $3.6 million in 2004, due to lower discount rates and changes in mortality assumptions.

Investor Verification Checklist

• Verify the timeline and cost savings associated with the transition of Bard Endoscopic Technologies manufacturing to CONMED facilities (expected completion 2006).
• Monitor the status and potential costs of the antitrust litigation against Johnson & Johnson.
• Assess the impact of the upcoming adoption of SFAS 123R on future earnings per share.
• Review the execution of the $7.7 million stock repurchase plan in Q2 2005.
• Track the resolution of the surgical lights product line termination and associated remaining costs ($1.3 million anticipated).